#None #Ascend Advanced Therapies #EpyQ Technology #AAV Plasmid

Ascend Advanced Therapies Strengthens IP Portfolio with EpyQ® Patent Defense

In a triumphant announcement on October 8, 2025, Ascend Advanced Therapies (Ascend) confirmed that its European patent, EP3722434, safeguarding their proprietary EpyQ® AAV plasmid technology, has been successfully defended against opposition at the European Patent Office (EPO). This crucial outcome underscores the robustness and novelty of Ascend's innovative approach to plasmid design and production in the rapidly advancing field of gene therapy.

The scrutiny faced in opposition proceedings at the EPO often presents formidable challenges to patent validity; thus, the decision to uphold the patent marks a pivotal moment for Ascend. Chief Scientific Officer Markus Hörer heralded this achievement as a significant milestone, emphasizing that defending the EpyQ® patent not only secures the company’s innovative edge but also bolsters its position as a leader in AAV plasmid technology. "This decision not only strengthens our patent portfolio but enhances our ability to support our partners in advancing gene therapy development within a secure intellectual property landscape," said Hörer.

Ascend's EpyQ® technology is lauded for its potential applications in gene therapies, which are evolving rapidly with new and innovative treatments emerging. The successful defense of this patent offers a solid groundwork for the continued advancement of EpyQ® technology, allowing Ascend to remain at the forefront of this dynamic field, delivering efficient plasmid and vector solutions that can drive progress in genetic medicine.

The company, which specializes in gene-to-GMP (Good Manufacturing Practice) development, was established in early 2023 following the acquisition of Freeline Therapeutics' Munich manufacturing assets and development team, which boasts AAV expertise dating back to 1991. In early 2024, Ascend expanded its operations in the United States with the acquisition of GMP manufacturing assets from Beacon Therapeutics in Alachua, Florida.

In a noteworthy collaboration established in late 2024, Ascend partnered with ABL, Inc. to enhance development, manufacturing, and fill/finish capabilities for gene therapies, vaccines, oncolytics, and immunotherapies. The company combines decades of therapeutic development experience in offering comprehensive CMC (Chemistry, Manufacturing, and Controls) support, thereby assisting clients throughout the conceptualization to commercialization process, striving for an optimal balance between yield, quality, and cost.

With a commitment to advancing gene therapy development, Ascend will continue to push the boundaries of AAV plasmid technology, demonstrating the ability to deliver high-quality, innovative solutions that meet the evolving demands of the healthcare landscape. Ascend recognizes that the success in patent defense is just the beginning, as it aims to leverage this robust IP foundation to explore new horizons in genetic medicine.

For more information about Ascend and to stay updated on its developments, visit www.ascend-adv.com, follow them on LinkedIn, or reach out via email at [email protected].

About Ascend Advanced Therapies

Ascend is a gene-to-GMP CDMO focusing on the high-quality and cost-effective development and manufacturing of advanced therapies. Since its inception, the company has rapidly evolved, thanks to strategic acquisitions that bolster its capabilities, ensuring it is well-positioned to provide innovative solutions in the clinical and commercial realms.

Foundational investors in Ascend include Abingworth, Ajinomoto, Cathay Health, Deerfield, Digitalis Ventures, DCVC Bio, EW Healthcare Partners, and more. Their financial backing reinforces the trust and expectations surrounding Ascend's contribution to the future of gene therapy.

As the field of gene therapy continues to flourish, Ascend remains dedicated to maintaining its pioneering spirit while driving innovation within this critical sector.